Tevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock.

Tevogen Bio Trading Down 7.0 %

NASDAQ:TVGN opened at $1.06 on Tuesday. The stock has a 50-day simple moving average of $1.36 and a 200 day simple moving average of $1.16. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $7.61.

Insider Transactions at Tevogen Bio

In other news, insider Neal Flomenberg sold 88,519 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the completion of the transaction, the insider now directly owns 4,040,485 shares in the company, valued at $4,444,533.50. This represents a 2.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 56.60% of the company's stock.

Institutional Trading of Tevogen Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new position in Tevogen Bio in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. boosted its holdings in shares of Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the last quarter. Barclays PLC grew its stake in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new position in Tevogen Bio during the fourth quarter worth $55,000. Finally, Northern Trust Corp raised its position in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads